UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000060320
Receipt number R000068958
Scientific Title Verification of the effect of honey intake on improving cough sensitivity in humans
Date of disclosure of the study information 2026/01/15
Last modified on 2026/01/10 20:13:15

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Verification of the effect of honey intake on improving cough sensitivity in humans

Acronym

Verification of the effect of honey intake on improving cough sensitivity

Scientific Title

Verification of the effect of honey intake on improving cough sensitivity in humans

Scientific Title:Acronym

Verification of the effect of honey intake on improving cough sensitivity

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To verify the effect of honey intake on improving cough sensitivity

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Cough threshold in the capsaicin cough sensitivity test
Japanese Newcastle Laryngeal Hypersensitivity Questionnaire(J-NLHQ)
VAS questionnaire

Key secondary outcomes

subjects' diary
doctor's findings according to the subjects' diary


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

To intake honey single time

Interventions/Control_2

To intake placebo single time

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

64 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Japanese males and females aged 20 to 64 years oldĀ at the time of informed consent
2) Healthy adults
3) Subjects who are concerned about coughing or throat discomfort
4) Subjects who regularly eat three meals a day
5) Subjects who Subjects who can perform informed consent
6) Subjects who can understand and comply with the management instructions during the study period

Key exclusion criteria

1) Subjects who regularly consume honey
2) Subjects unable to maintain a regular daily routine
3) Pregnant, intending to become pregnant, or breastfeeding
4) Subjects participating in other clinical tests or studies during the test period
5) Subjects who are supposed not to be proper by the investigator
6) Subjects planning medication treatment for hay fever during the test period
7) Subjects unable to discontinue medications that may affect test results (e.g., cough suppressants, cold remedies, allergy suppressants) 7 days prior to the test
8) Subjects at risk of allergic reactions to test components (honey, chili pepper extract)
9) Subjects planning to change their diet during the test period
10) Subjects with cardiovascular or respiratory diseases, asthma, severe allergic diseases, liver dysfunction, kidney or heart disease, organ dysfunction, diabetes, or other serious illnesses
11) Subjects with a history of major gastrointestinal surgery (gastrectomy, gastrointestinal anastomosis, intestinal resection, etc.)
12) Subjects who consume excessive amounts of alcohol (equivalent to 20g of pure alcohol or more per day)
13) Smokers (or individuals living with smokers)
14) Subjects experiencing hay fever symptoms during the test period

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Takashi
Middle name
Last name Koikeda

Organization

Shiba Palace Clinic

Division name

Chair

Zip code

105-0013

Address

DaiwaA Hamamatsucho Bldg. 6F, 1-9-10, Hamamatsucho, Minato-ku, Tokyo, 105-0013, JAPAN

TEL

03-5408-1590

Email

rinri@s-palace-clinic.com


Public contact

Name of contact person

1st name Ko
Middle name
Last name Masuda

Organization

SOUKEN Co., Ltd

Division name

Management Division

Zip code

105-0013

Address

DaiwaA Hamamatsucho Bldg. 3F, 1-9-10, Hamamatsucho, Minato-ku, Tokyo, 105-0013, JAPAN

TEL

03-5408-1555

Homepage URL


Email

rinri@s-palace-clinic.com


Sponsor or person

Institute

Shiba Palace Clinic

Institute

Department

Personal name



Funding Source

Organization

Yamada Bee Farm

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Shiba Palace Clinic Ethics Review Committee

Address

DaiwaA Hamamatsucho Bldg. 6F, 1-9-10, Hamamatsucho, Minato-ku, Tokyo, 105-0013, JAPAN

Tel

03-5408-1599

Email

rinri@s-palace-clinic.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 01 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2025 Year 12 Month 24 Day

Date of IRB

2025 Year 12 Month 25 Day

Anticipated trial start date

2026 Year 02 Month 15 Day

Last follow-up date

2026 Year 04 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2026 Year 01 Month 10 Day

Last modified on

2026 Year 01 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068958